Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Fluorinated Gamma-carboline Derivatives as Promising Neuroprotective Candidates. Structure-Activity Relationships.

Central nervous system agents in medicinal chemistry·2026

Same author

Novel Cytotoxic Pt(IV) Compounds with Improved Safety Profiles.

International journal of molecular sciences·2026

Same author

Mitochondrial calcium overload is the trigger for carbon monoxide neurotoxicity.

Cell death & disease·2025

Same author

Efficient Decontamination of Organophosphate-Based Pesticides and Nerve Agent Simulants Mediated by N‑Containing Nucleophiles.

ACS omega·2025

Same author

Instantaneous Hydrolysis of Methyl Paraoxon Nerve Agent Simulant Is Catalyzed by Nontoxic Aminoguanidine Imines.

ACS omega·2025

Same author

Discovery of Novel 2-Oxindoles as Compounds with Antiglaucoma Activity.

ChemMedChem·2025

Search research articles

Related Experiment Video

Updated: Apr 30, 2026

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils

Published on: September 28, 2019

Dimebon attenuates the Aβ-induced mitochondrial permeabilization.

Elena F Shevtsova, Daria V Vinogradova, Elena G Kireeva

¹Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, 142432, Russia. shevtsova@ipac.ac.ru.

Current Alzheimer Research

|May 8, 2014

Summary

Dimebon protects brain mitochondria from neurodegeneration by enhancing calcium retention capacity and resisting amyloid-beta induced damage. This drug shows potential for treating neurodegenerative diseases.

More Related Videos

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess

Published on: June 1, 2022

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)

Published on: January 10, 2025

Related Experiment Videos

Last Updated: Apr 30, 2026

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils

Published on: September 28, 2019

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess

Published on: June 1, 2022

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)

Published on: January 10, 2025

Area of Science:

Neuroscience
Biochemistry
Pharmacology

Background:

The neuroprotective effects of dimebon are hypothesized to involve protection of brain mitochondria.
Understanding dimebon's influence on mitochondrial function is crucial for elucidating its therapeutic potential.

Purpose of the Study:

To investigate the influence of dimebon on isolated rat brain and liver mitochondria.
To understand dimebon's role in mitochondrial permeability transition (MPT) and calcium retention capacity (CRC).

Main Methods:

Isolated rat brain and liver mitochondria were used.
Mitochondrial permeability transition (MPT) was induced by calcium ions and atractyloside.
Calcium retention capacity (CRC) was measured using three different assays.
Amyloid-beta peptide was used to induce mitochondrial toxicity.

Main Results:

Dimebon enhanced mitochondrial resistance to calcium-induced MPT, but not swelling, in the presence of atractyloside.
Dimebon did not inhibit MPT in de-energized mitochondria or affect adenine nucleotide translocase (ANT) conformational changes, unlike cyclosporine A.
Dimebon's effect on CRC depended on calcium addition mode, increasing CRC in bolus mode and prolonging calcium efflux lag time.
Dimebon effectively counteracted amyloid-beta-induced mitochondrial swelling and decreased CRC.

Conclusions:

Dimebon protects brain mitochondria against amyloid-beta toxicity by modulating calcium handling.
Dimebon's mechanism differs from classical MPT inhibitors like CsA.
These findings support dimebon's potential as a neuroprotective agent against mitochondrial dysfunction in neurodegenerative diseases.